Therefore, p300 inhibition may be more applicable during late adulthood or for the treatment of age-related diseases that rely on elevated p300 activity such as cancer and neurodegenerative diseases.50,51 Several chemical inhibitors with varying potency and selectivity for p300 have already been tested for their potential anticancer properties, including anacardic acid,52 C646,53 and A485.54 This evidence concerns the gene EP300 and cancer.